“There was about a 32.5% survival advantage for patients with that triple therapy,” says Michael S. Cookson, MD, MMHC.
In this video, Michael S. Cookson, MD, MMHC, discusses the background and notable findings of the study, “Darolutamide in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer: overall survival and other outcomes of the phase 3 ARASENS trial,” which will be presented at the 2022 South Central Section of the AUA Annual Meeting in Coronado, California. professor and chair of urology at the University of Oklahoma Health Sciences Center in Oklahoma City, is co-editor in chief of Urology Times.®
Long-term follow-up supports pembrolizumab monotherapy in BCG-unresponsive NMIBC
December 2nd 2022Pembrolizumab monotherapy continued to demonstrate durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with BCG-unresponsive NMIBC.
2 Clarke Drive
Cranbury, NJ 08512